Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Genome-Wide Assessment Reveals Ancestral Differences in Homozygosity Patterns Potentially Linked to Parkinson's Disease Etiology

  • Global Parkinson’s Genetics Program (GP2)
  • Stellenbosch University
  • Universidad del Desarrollo
  • National Institutes of Health
  • University of Khartoum
  • Laboratorio Clínico de Enfermedades Neurodegenerativas
  • National Taiwan University and Academia Sinica
  • Pavol Jozef Šafárik University
  • University College London
  • Northwestern University
  • Harvard University
  • Grupo de Neurociencias (GNA)
  • German Centre for Neurodegenerative Diseases (DZNE)

Abstract

BACKGROUND: Recessive genetic variation and extended runs of homozygosity (ROHs) may contribute to the unexplained heritability of Parkinson's disease (PD), particularly in diverse and understudied populations.

OBJECTIVE: We conducted the first large-scale, multi-ancestral investigation of PD to examine the impact of genome-wide homozygosity on disease risk and age at onset (AAO). Using genotyping, imputed, and whole-genome sequencing data from 36,127 PD cases and 19,475 controls across nine ancestral populations from the Global Parkinson's Genetics Program, we aimed to identify novel regions of homozygosity contributing to PD heritability.

METHODS: We analyzed ROHs for total length (SROH), number (NROH), average length (AVROH), and genomic inbreeding coefficient (FROH). ROHs were intersected with known PD, pallido-pyramidal syndrome, and atypical parkinsonism gene regions and risk loci to assess pleomorphic or pleiotropic contributions. Homozygosity mapping identified ROH overlaps in families, consanguineous individuals, and early-onset PD (EOPD) cases.

RESULTS: Significant differences in SROH, AVROH, NROH, and FROH were observed between case status across ancestries, persisting after excluding known PD-associated recessive genes. Our analysis revealed distinct patterns of ROH enrichment associated with AAO, suggesting recessive genetic modifiers of PD. Homozygosity mapping was used to prioritize 52 variants either segregating in families or present in individuals with consanguinity. In total, 1,559 ROHs in consanguineous individuals and EOPD overlapped known PD gene regions and risk loci.

CONCLUSIONS: ROH regions contribute to PD heritability across ancestries, partly reflecting recessive genetic architecture. Larger and more diverse whole-genome sequencing studies are needed to identify rare recessive variants influencing PD risk. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

OriginalspracheEnglisch
ZeitschriftMovement disorders : official journal of the Movement Disorder Society
Jahrgang41
Ausgabenummer5
Seiten (von - bis)1128-1140
Seitenumfang13
ISSN0885-3185
PublikationsstatusVeröffentlicht - 05.2026
Extern publiziertJa

Fördermittel

I.F.M has received honorarium from the Parkinson's Foundation PD GENEration Steering Committee and Aligning Science Across Parkinson's Global Parkinson Genetic Program (ASAP‐GP2). K.S. is funded by The Michael J. Fox Foundation (MJFF) and Aligning Sciences Across Parkinson's Disease Global Parkinson Genetic Program (ASAP‐GP2). Z.‐H.F. is supported by the Aligning Science Across Parkinson's (ASAP) Global Parkinson's Genetics Program (GP2) and receives GP2 salary support from The Michael J. Fox Foundation for Parkinson's Research. I.M. was supported by grants from NIH (R01NS112499‐01A1), The Michael J. Fox Foundation (MJFF), and Aligning Sciences Across Parkinson's Disease Global Parkinson Genetic Program (ASAP‐GP2). J.A.U. is funded by the Rainwater Charitable Foundation through the Tau consortium and the Center for Alzheimer's and Related Dementias. N.E.M. is supported by the NIH (1K08NS131581) and ASAP GP2; he is a member of the steering committee of the PD GENEration study and receives an honorarium from the Parkinson's Foundation. H.M. is employed by UCL. In the last 12 months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics, and Amylyx; lecture fees/honoraria—BMJ, Kyowa Kirin, Movement Disorders Society. Research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, Medical Research Council, The Michael J Fox Foundation. H.M. is a coapplicant on a patent application related to C9ORF72—Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). A.Z. is funded by the MCSBHT—Medical College of Saint Bartholomew's Hospital Trust. E.P‐P. is supported by the Chilean National Agency for Investigation and Development, ANID (Fondecyt grant 1221,464). C.F.H. is supported by the Chilean National Agency for Investigation and Development, ANID (Beca Doctorado Nacional 2020 Folio 21,201,541). M.K., E.E., A.J.H‐M., P.‐J.K., M.O., I.J.K.S., and S.B.‐C. do not have any financial disclosures. Relevant conflicts of interest/financial disclosures: This work was supported and guided by the “GP2 Trainee Network” and formed part of the Global Parkinson's Genetics Program (GP2) Hackathon 2023. The data used for the analysis were obtained from the GP2 ( https://gp2.org ), which was funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research ( https://michaeljfox.org/ ). A complete list of GP2 members is available at https://gp2.org . All figures were created using BioRender ( https://www.biorender.com/ ). We thank Caroline Pantazis for her work as scientific project manager for this project. We thank Paige Brown Jarreau for her meticulous editing of this manuscript. . This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project numbers ZO1 AG000535 and ZIA AG000949, as well as the National Institute of Neurological Disorders and Stroke (NINDS, program # ZIANS003154) and the National Human Genome Research Institute (NHGRI). Additional funding was provided by The Michael J. Fox Foundation for Parkinson's Research through grant MJFF‐009421/17483. This work utilized the computational resources of the NIH STRIDES Initiative ( https://cloud.nih.gov ) through the Other Transaction agreement—Azure: OT2OD032100, Google Cloud Platform: OT2OD027060, Amazon Web Services: OT2OD027852. This work utilized the computational resources of the NIH HPC Biowulf cluster ( https://hpc.nih.gov ). The contributions of the NIH author(s) were made as part of their official duties as NIH federal employees are in compliance with agency policy requirements, and are considered works of the United States government. However, the findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. We have received an exception to the Data and Statistics Dissemination Policy from the All of Us Resource Access Board. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085 U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants. This research has been conducted using the UK Biobank Resource under application number 33601. K.S. is funded by The Michael J. Fox Foundation (MJFF) and Aligning Sciences Across Parkinson's Disease Global Parkinson Genetic Program (ASAP‐GP2). Z.‐H.F. is supported by the Aligning Science Across Parkinson's (ASAP) Global Parkinson's Genetics Program (GP2) and receives GP2 salary support from The Michael J. Fox Foundation for Parkinson's Research. I.M. was supported by grants from NIH (R01NS112499‐01A1), The Michael J. Fox Foundation (MJFF), and Aligning Sciences Across Parkinson's Disease Global Parkinson Genetic Program (ASAP‐GP2). J.A.U. is funded by The Rainwater Charitable Foundation through the Tau consortium and the Center for Alzheimer's and Related Dementias. N.E.M. is supported by the NIH (1K08NS131581) and ASAP GP2; he is a member of the steering committee of the PD GENEration study and receives an honorarium from the Parkinson's Foundation. H.M. is employed by UCL. In the last 12 months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics, and Amylyx; lecture fees/honoraria—BMJ, Kyowa Kirin, Movement Disorders Society. Research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, Medical Research Council, The Michael J. Fox Foundation. H.M. is a coapplicant on a patent application related to C9ORF72—Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). A.Z. is funded by the MCSBHT—Medical College of Saint Bartholomew's Hospital Trust. E.P‐P. is supported by the Chilean National Agency for Investigation and Development, ANID (Fondecyt grant 1221464). C.F.H. is supported by the Chilean National Agency for Investigation and Development, ANID (Beca Doctorado Nacional 2020 Folio 21201541). M.K., E.E., A.J.H‐M., P‐J.K., M.O., I.J.K.S., and S.B‐C. do not have any financial disclosures. For open access, the author has applied a CC BY public copyright license to all author‐accepted manuscripts arising from this submission This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project numbers ZO1 AG000535 and ZIA AG000949, as well as the National Institute of Neurological Disorders and Stroke (NINDS, program # ZIANS003154) and the National Human Genome Research Institute (NHGRI). Additional funding was provided by The Michael J. Fox Foundation for Parkinson's Research through grant MJFF‐009421/17483. Funding agencies:

TrägerTrägernummer
Parkinson's Foundation
Rainwater Charitable Foundation
National Institute of Neurological Disorders and Stroke
Medical Research Council
National Institutes of HealthR01NS112499‐01A1
Chilean National Agency for Investigation and Development
Agencia Nacional de Investigación y Desarrollo
PSP Association
Cure Parkinson's Trust
Aligning Science Across Parkinson's
Michael J. Fox Foundation for Parkinson's Research
National Institute on Aging
Fondo Nacional de Desarrollo Científico y Tecnológico21201541, 1221,464
Department of Health and Human ServicesZIA AG000949, ZO1 AG000535
National Human Genome Research InstituteASAP‐GP2, 3 OT2 OD023205, MJFF‐009421/17483, 3 OT2 OD023206, 1 OT2 OD026555, 1 OT2 OD025276, 1 OT2 OD025277, AOD 16037, 1 U24 OD023121, R01NS112499‐01A1, 1 U24 OD023163, U24 OD023176, HHSN 263201600085
NINDSZIANS003154
Center for Alzheimer's and Related Dementias1K08NS131581

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Genome-Wide Assessment Reveals Ancestral Differences in Homozygosity Patterns Potentially Linked to Parkinson's Disease Etiology“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Dieses zitieren